Castle Biosciences is executing a strategic pivot toward commercial expansion, evidenced by a 20.1% YoY revenue surge in Q2 2026 to $103.5M, yet this growth is accompanied by persistent gross margin compression (down to 77.1% from 83.3% two years prior) and escalating SG&A costs, which have risen 36% since Q1 2024.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.13+62.6% vs -$0.35 | $103M+10.9% vs $93M |
Q3 2026 Jul 30, 2026 | -$0.07+82.8% vs -$0.41 | $104M+20.1% vs $86M |
Q2 2026 May 6, 2026 | -$0.49+0.0% vs -$0.49 | $84M+6.3% vs $79M |
Q1 2026 Feb 26, 2026 | -$0.08+65.2% vs -$0.23 | $87M+8.9% vs $80M |
Castle Biosciences NASDAQ: CSTL raised its full-year revenue outlook after reporting 24% third-quarter revenue growth, driven primarily by demand for its TissueCypher test.
Castle Biosciences, Inc. (CSTL) Q3 2026 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.02 per share a year ago.
Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025 TissueCypher ® test report volume increased 47% over Q3 2025 Raising full-year 2026 revenue guidance to $385-395 million from $365-375 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Nov. 5, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, 2026.
Benchmark CSTL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Castle Biosciences, Inc. (CSTL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $32.52 | $986.33M | -43.29 | 3.66% | -6.1% | -4.89% | — | |
| $310.67 | $44.49B | -271.73 | 35.9% | -5.66% | -9.18% | — | |
| $24.16 | $1.93B | 15.77 | 16.01% | 21.8% | 9.27% | — | |
| $2.88 | $711.44M | -12.98 | 22.09% | -11.85% | -35.3% | — | |
| $23.74 | $674.23M | -7.22 | 13.83% | -27.53% | -8.8% | — | |
| $150.87 | $20.01B | -41.81 | 32.88% | -37.93% | — | — |
Castle Biosciences, Inc. (CSTL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Castle Biosciences, Inc. (CSTL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
May 29, 2026·SEC
May 6, 2026·SEC
Get notified when CSTL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Castle Biosciences, Inc. (CSTL) stock FAQ — growth, dividends, profitability & financials explained
Castle Biosciences, Inc. (CSTL) reported $377.1M in revenue over the trailing twelve months. Revenue was $344.2M in fiscal year 2025. That is 2403% more than the $13.8M of fiscal year 2017.
Castle Biosciences, Inc. (CSTL) grew revenue by 9.8% over the trailing twelve months, compared with the twelve months before.
No. Castle Biosciences, Inc. (CSTL) reported a net loss of $23.0M over the trailing twelve months.
Castle Biosciences, Inc. (CSTL) had a return on equity (ROE) of -4.9% over the trailing twelve months. A negative ROE means the company lost money over the period.
Castle Biosciences, Inc. (CSTL) generated $4.0M in free cash flow over the trailing twelve months.
